Todas las investigaciones
Activo, no reclutandoFASE3INTERVENCIONISTA

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

This research study, called ACCLAIM-Lp(a), is testing a new medication called lepodisiran. The main goal is to see if lepodisiran can lower the risk of serious heart problems, like heart attacks and strokes, in adults who have high levels of a type of fat in their blood called lipoprotein(a) (Lp(a)). Participants selected for this study either already have heart disease or are at a high risk of developing it. The study drug will be given as an injection just under the skin. We're also looking to enrol more people to understand how different ways of giving the drug might affect Lp(a) levels. This is a Phase 3 trial, meaning it's one of the final steps before a drug might be considered for wider use.

De un vistazo

Estado
Activo, no reclutando
Fase
FASE3
Patrocinador
Eli Lilly and Company
Objetivo de inscripción
17,300
Inicio
05 Mar 2024
Estimación de finalización
01 Mar 2029

¿De qué trata este estudio?

This important research study, called ACCLAIM-Lp(a), is investigating a new medication called lepodisiran. The main purpose is to find out if this medicine can help lower the risk of serious heart and blood vessel problems, such as heart attacks and strokes, in people who have particularly high levels of a substance in their blood called lipoprotein(a), often shortened to Lp(a).

Lp(a) is a type of fat and protein found in your blood, and high levels of it have been linked to an increased risk of heart disease. While there are treatments for other types of cholesterol, there aren't many specific treatments for high Lp(a) yet. That's why this study is so important — it's exploring a new way to potentially protect people from future heart and stroke events.

The study will involve adults who either already have heart or blood vessel disease (like after a heart attack or needing a procedure to open blocked arteries) or who are considered at high risk of having a heart attack or stroke. Participants will be given the study medication, lepodisiran, as an injection under the skin. Another part of the study will involve additional participants to explore if giving the medicine in different ways can also effectively lower Lp(a) levels.

Puntos clave

  • This study tests a new drug, lepodisiran, for high lipoprotein(a).
  • It aims to lower the risk of heart attacks and strokes.
  • It's for adults with existing heart disease or those at high risk.
  • The drug is given as an injection under the skin.
  • Participation involves regular clinic visits and health monitoring.
  • Puedes dejar de participar en cualquier momento.

¿Quién puede ser elegible?

To join this study, you would need to meet certain requirements. Firstly, you must be 18 years or older and have a high level of lipoprotein(a) (Lp(a)) in your blood, specifically 175 nanomoles per litre or higher.

Secondly, you must either have existing heart or blood vessel disease (like heart disease or blockages in arteries) that has caused an event (like a heart attack) or required a procedure. Alternatively, if you are 55 years or older, you might be eligible if you are at high risk of a first heart attack or stroke. This could include having a known history of conditions like coronary artery disease, narrowing of major arteries, or blocked arteries in your legs, even if you haven't had an event yet. It could also apply if you have a family history of very high cholesterol (familial hypercholesteremia) or a combination of several other risk factors.

However, some conditions would mean you cannot take part. For example, if you've had a recent major heart event or surgery in the past two months, have very high blood pressure that isn't under control, severe heart failure, or have had a specific blood treatment called lipoprotein apheresis recently. Also, people with serious kidney or liver problems would not be suitable for this study.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. ¿Tienes 18 años o más?
  2. Do you have high lipoprotein(a) (Lp(a)) levels of 175 nmol/L or higher?
  3. Have you had a heart attack, stroke, or a procedure for blocked arteries, OR are you 55 or older with other heart risk factors?
  4. Have you NOT had a major heart event or surgery in the past 2 months?
  5. Do you have well-controlled blood pressure?
  6. Do you NOT have severe problems with your kidneys or liver?
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

Taking part in this study would involve regularly visiting a clinic for health checks and to receive the study medication. This medicine, lepodisiran, will be given as an injection just under your skin. You will either receive the active drug or a placebo (a dummy drug with no active ingredients). This is decided randomly, like flipping a coin, and neither you nor your study doctor will know which you are receiving. The study team will monitor your health closely, including taking blood samples to check your Lp(a) levels and overall health. They will also keep track of any changes in your health or any new symptoms you experience. The total duration of your participation in the study, including all follow-up, will be discussed in detail by the study team.

Riesgos y beneficios potenciales

Participating in research always comes with potential benefits and risks. You might benefit from closer medical attention and possibly receive a new treatment that could improve your health, though this is not guaranteed as you might receive a placebo. There could be risks and side effects from the study medication, similar to any medicine, and these will be fully explained to you. Although every effort is made to minimise risks, some unknown side effects could occur. You are always free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (928)

  • Birmingham Clinical Research
    Código postal verificado
    Birmingham, United States
  • Alliance for Multispecialty Research, LLC
    Código postal verificado
    Daphne, Estados Unidos
  • SEC Clinical Research
    Código postal verificado
    Dothan, Estados Unidos
  • Alliance for Multispecialty Research, LLC
    Código postal verificado
    Mobile, United States
  • Mobile Heart Specialists
    Código postal verificado
    Mobile, United States
  • Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC
    Código postal verificado
    Gilbert, United States
  • Mercy Gilbert Medical Center
    Código postal verificado
    Gilbert, United States
  • Sun City Clinical Research
    Código postal verificado
    Glendale, United States
  • Elite Clinical Studies, LLC
    Código postal verificado
    Phoenix, Estados Unidos
  • Helios Clinical Research - Phoenix
    Código postal verificado
    Phoenix, Estados Unidos
  • Absolute Clinical Research
    Código postal verificado
    Phoenix, Estados Unidos
  • Clinical Research Institute of Arizona (CRI) - Sun City West
    Código postal verificado
    Sun City West, United States

Preguntas comunes

What is lipoprotein(a)?

Lipoprotein(a), or Lp(a), is a type of fat and protein particle in your blood. High levels of Lp(a) are linked to a higher risk of heart disease and stroke.

¿Por qué es importante este estudio?

This study is important because there are currently limited treatments specifically for high Lp(a). It aims to find a new way to reduce heart disease and stroke risk.

What is a Phase 3 study?

A Phase 3 study is one of the final stages of clinical research. It involves a larger number of people to confirm the safety and effectiveness of a new drug before it can be considered for general use.

¿Qué es un placebo?

A placebo is a 'dummy' treatment that looks just like the study drug but has no active ingredients. It helps researchers compare the effects of the active drug to no treatment.

Will I know if I'm getting the actual drug or the placebo?

No, during the main part of the study, neither you nor your study doctor will know whether you are receiving the active drug or the placebo. This helps ensure unbiased results.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.